LA JOLLA, Calif.--(BUSINESS WIRE)--Apr. 14, 2022--
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference call and webcast on Tuesday, May 3, 2022 at 5:00 p.m. Eastern Time (ET) to discuss the Company's first-quarter 2022 operating and financial highlights. In advance of the call on May 3, 2022, DermTech will issue its first-quarter 2022 earnings press release. To participate in the teleconference, callers can dial the following numbers:
844-467-7114 (toll-free, U.S.)
409-231-2086 (international)
Conference ID: 6584229
For those unable to participate in the live call and webcast, a webcast replay will be available on the Company’s website shortly after the conclusion of the call.
About DermTech:
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information, please visit DermTech.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220414005260/en/
DermTech
Steve Kunszabo (Senior Director, Investor Relations)
steve.kunszabo@dermtech.com
Source: DermTech, Inc.
